<code id='D5C0092FE3'></code><style id='D5C0092FE3'></style>
    • <acronym id='D5C0092FE3'></acronym>
      <center id='D5C0092FE3'><center id='D5C0092FE3'><tfoot id='D5C0092FE3'></tfoot></center><abbr id='D5C0092FE3'><dir id='D5C0092FE3'><tfoot id='D5C0092FE3'></tfoot><noframes id='D5C0092FE3'>

    • <optgroup id='D5C0092FE3'><strike id='D5C0092FE3'><sup id='D5C0092FE3'></sup></strike><code id='D5C0092FE3'></code></optgroup>
        1. <b id='D5C0092FE3'><label id='D5C0092FE3'><select id='D5C0092FE3'><dt id='D5C0092FE3'><span id='D5C0092FE3'></span></dt></select></label></b><u id='D5C0092FE3'></u>
          <i id='D5C0092FE3'><strike id='D5C0092FE3'><tt id='D5C0092FE3'><pre id='D5C0092FE3'></pre></tt></strike></i>

          explore

          explore

          author:knowledge    Page View:454
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Printout prescription drug information shouldn’t go digital
          Printout prescription drug information shouldn’t go digital

          AdobeGettinganewprescriptioncanbeoverwhelming:medicationschedules,foodstoeatoravoid,interactionsbetw

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          AstraZeneca challenges Medicare drug negotiation program

          AstraZenecaissuingtheBidenadministrationtostopanewMedicaredrugpricenegotiationprogram.AdobeWASHINGTO